We are live on ! Find out more
PHS

PFM Health Sciences Portfolio holdings

AUM $1.1B
1-Year Est. Return 57.92%
This Fund
S&P 500
This Quarter Est. Return
-5.61%
1 Year Est. Return
+57.92%
3 Year Est. Return
+183.93%
5 Year Est. Return
+283%
10 Year Est. Return
+2,507.28%
AUM
$2.67B
AUM Growth
-$263M
Cap. Flow
-$103M
Cap. Flow %
-3.85%
Top 10 Hldgs %
36.14%
Holding
81
New
10
Increased
17
Reduced
15
Closed
13

Top Buys

Rank Stock Value
1
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$74.9M
2
JNJ icon
Johnson & Johnson
JNJ
+$44.2M
3
BDX icon
Becton Dickinson
BDX
+$41.6M
4
SRRA
Sierra Oncology, Inc. Common Stock
SRRA
+$30.5M
5
MOH icon
Molina Healthcare
MOH
+$22.7M

Top Sells

Rank Stock Value
1
ABBV icon
AbbVie
ABBV
+$124M
2
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$46.3M
3
SGEN
Seagen Inc. Common Stock
SGEN
+$41.5M
4
NBIX icon
Neurocrine Biosciences
NBIX
+$33.6M
5
HCA icon
HCA Healthcare
HCA
+$29M

Sector Composition

Rank Sector Weight
1 Healthcare 92.79%
2 Financials 0.34%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AERI
51
DELISTED
Aerie Pharmaceuticals
AERI
$9.91M 0.37%
1,088,566
– –
QURE icon
52
uniQure
QURE
$3.15B
$9.66M 0.36%
+534,624
New +$9.34M
PMVP icon
53
PMV Pharmaceuticals
PMVP
$62.9M
$9.29M 0.35%
446,300
+157,966
+55% +$2.79M
PRAX icon
54
Praxis Precision Medicines
PRAX
$10.3B
$8.83M 0.33%
57,655
+15,261
+36% +$3.13M
VERV
55
DELISTED
Verve Therapeutics
VERV
$8.44M 0.32%
+369,765
New +$10.6M
CANO
56
DELISTED
Cano Health, Inc.
CANO
$8.27M 0.31%
13,019
-6,127
-32% -$3.86M
CCCC icon
57
C4 Therapeutics
CCCC
$402M
$6.91M 0.26%
+284,772
New +$6.91M
IOBT
58
DELISTED
IO Biotech
IOBT
$6.65M 0.25%
1,362,144
– –
PRDS
59
DELISTED
Pardes Biosciences, Inc. Common Stock
PRDS
$5.27M 0.2%
730,357
+368,829
+102% +$3.63M
ADAP
60
DELISTED
Adaptimmune Therapeutics
ADAP
$4.89M 0.18%
2,374,674
-826,392
-26% -$2.23M
BLSA
61
DELISTED
BCLS Acquisition Corp. Class A Ordinary Shares
BLSA
$4.58M 0.17%
464,103
– –
JYAC
62
DELISTED
Jiya Acquisition Corp. Class A Common Stock
JYAC
$4.56M 0.17%
464,103
– –
GBIO
63
DELISTED
Generation Bio
GBIO
$4.21M 0.16%
+57,428
New +$3.33M
LAB icon
64
Standard BioTools
LAB
$313M
$3.52M 0.13%
980,505
– –
SANA icon
65
Sana Biotechnology
SANA
$949M
$2.94M 0.11%
+355,272
New +$2.87M
HOWL icon
66
Werewolf Therapeutics
HOWL
$19.6M
$2.58M 0.1%
585,327
+185,327
+46% +$1.3M
ABBV icon
67
AbbVie
ABBV
$431B
– –
-916,496
Closed -$124M
BFLY icon
68
Butterfly Network
BFLY
$2.21B
– –
-1,828,311
Closed -$12.2M
INCY icon
69
Incyte
INCY
$24B
– –
-129,428
Closed -$9.5M
LUNG icon
70
Pulmonx
LUNG
$88M
– –
-209,193
Closed -$6.71M
NBIX icon
71
Neurocrine Biosciences
NBIX
$16.2B
– –
-394,058
Closed -$33.6M
NVAX icon
72
Novavax
NVAX
$1.27B
– –
-88,663
Closed -$12.7M
OEF icon
73
CALL
iShares S&P 100 ETF
OEF
$20.5B
– –
-272,800
Closed -$41.6M
PRCT icon
74
Procept Biorobotics
PRCT
$1.14B
– –
-65,000
Closed -$1.63M
XNTK icon
75
CALL
State Street SPDR NYSE Technology ETF
XNTK
$2.19B
– –
-246,100
Closed -$27.6M
1 2
3
4

Similar funds

DAM
Delta Asset Management Memphis, Tennessee $1.1B AUM 14.89% 1-Year Est. Return
MAM
Mark Asset Management New York $1.1B AUM 43.79% 1-Year Est. Return
DAM
DLD Asset Management New York $1.1B AUM 4.68% 1-Year Est. Return
KCM
Khrom Capital Management Miami Beach, Florida $1.09B AUM 14.82% 1-Year Est. Return
MIA
MMBG Investment Advisors Miami, Florida $1.09B AUM 30.96% 1-Year Est. Return
YL
YCG LLC Austin, Texas $1.1B AUM 4.87% 1-Year Est. Return
SL
Sentinus LLC Oak Brook, Illinois $1.11B AUM 17.13% 1-Year Est. Return
PWA
Pitcairn Wealth Advisors Conshohocken, Pennsylvania $1.09B AUM

PFM Health Sciences's Q1 2022 Portfolio in Review

As of Q1 2022, PFM Health Sciences held 81 positions worth $2.67B, down 8.9% from $2.94B the previous quarter. Its ten largest holdings account for 36% of the portfolio.

PFM Health Sciences withdrew a net $103M in Q1 2022, closing 13 positions and reducing 15 holdings. Its most notable exit was AbbVie, an estimated $124M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, down from 94% a quarter earlier, followed by Financials.

Against the trend, PFM Health Sciences opened a new position in Jazz Pharmaceuticals worth $80.4M.

  • PFM Health Sciences's largest Q1 2022 buy was Jazz Pharmaceuticals: 516,406 shares worth $80.4M.
  • PFM Health Sciences added most to Johnson & Johnson in Q1 2022, an estimated $44.2M increase.
  • PFM Health Sciences's biggest Q1 2022 reduction was HCA Healthcare, cutting an estimated $29M.
  • PFM Health Sciences fully exited AbbVie in Q1 2022, selling an estimated $124M.
  • PFM Health Sciences's ten largest holdings make up 36% of its $2.67B portfolio in Q1 2022.
  • PFM Health Sciences opened 10 new positions and closed 13 in Q1 2022.
  • PFM Health Sciences's portfolio value fell 8.9% quarter-over-quarter to $2.67B.

Based on PFM Health Sciences's 13F filing for Q1 2022, filed 16 May 2022.